What geriatricians need to know about cannabinoids for older patients
Cannabinoids show some efficacy for pain and chemotherapy nausea in older adults, with risks comparable to other analgesics, but few studies have specifically enrolled elderly patients.
Quick Facts
What This Study Found
From 35 relevant studies, cannabinoids demonstrate some efficacy for pain and chemotherapy-related nausea. Limited data suggest potential benefits for spasticity and anxiety. Risks in older patients appear moderate and comparable to other analgesic drug classes. However, research quality is weak, and few older patients have been specifically enrolled in cannabinoid studies.
Key Numbers
35 studies identified. Evidence for pain and nausea. Limited data for spasticity and anxiety. Few older patients enrolled in existing studies.
How They Did This
Narrative literature review searching CENTRAL, Medline, Embase, CINAHL, psycINFO, Cochrane, and Web of Science. 35 studies identified as relevant.
Why This Research Matters
Older adults are the fastest-growing group of medical cannabis users but are also more vulnerable to adverse effects like falls, cognitive impairment, and drug interactions.
The Bigger Picture
The irony is that older adults have the most conditions that cannabinoids might help (chronic pain, nausea, spasticity) but are the least-studied population for these treatments.
What This Study Doesn't Tell Us
Narrative review. Weak underlying research quality. Few studies specifically enrolled older adults. Extrapolation from younger populations may not be valid.
Questions This Raises
- ?Are older adults at higher risk for cannabinoid side effects like falls and confusion?
- ?What drug interactions should geriatricians watch for?
Trust & Context
- Key Stat:
- Few older patients enrolled in cannabinoid studies
- Evidence Grade:
- Narrative review of weak-quality evidence, with limited age-specific data.
- Study Age:
- 2020 review.
- Original Title:
- Cannabinoids in the Older Person: A Literature Review.
- Published In:
- Geriatrics (Basel, Switzerland), 5(1) (2020)
- Database ID:
- RTHC-02413
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is medical cannabis safe for elderly patients?
This review found risks appear moderate and comparable to other analgesics, but few studies have specifically enrolled older adults, making definitive safety conclusions difficult.
What might cannabinoids help with in older adults?
The strongest evidence is for pain and chemotherapy-related nausea, with limited data suggesting possible benefits for spasticity and anxiety.
Read More on RethinkTHC
- cannabis-cardiovascular-heart-risk-stroke
- cannabis-heart-cardiovascular-risk
- coughing-up-stuff-after-quitting-weed
- lung-recovery-after-quitting-smoking-weed
- lung-recovery-quitting-weed
- quitting-weed-female-hormones
- quitting-weed-weight-gain-loss-diet-appetite
- sex-after-quitting-weed
- weed-DUI-driving-impaired-cannabis-laws
- weed-acne-skin
- weed-fertility-sperm
- weed-gut-digestion-problems
- weed-heart-health
- weed-testosterone-levels
Cite This Study
https://rethinkthc.com/research/RTHC-02413APA
Beedham, William; Sbai, Magda; Allison, Isabel; Coary, Roisin; Shipway, David. (2020). Cannabinoids in the Older Person: A Literature Review.. Geriatrics (Basel, Switzerland), 5(1). https://doi.org/10.3390/geriatrics5010002
MLA
Beedham, William, et al. "Cannabinoids in the Older Person: A Literature Review.." Geriatrics (Basel, 2020. https://doi.org/10.3390/geriatrics5010002
RethinkTHC
RethinkTHC Research Database. "Cannabinoids in the Older Person: A Literature Review." RTHC-02413. Retrieved from https://rethinkthc.com/research/beedham-2020-cannabinoids-in-the-older
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.